**FIG. 1**

3/20

FIG. 5

(SEQ ID NO: 4)

Human Luteinizing Hormone (LH)

1 8 L1 33
SREPLRPWCHPINAILAVEKEGCPVCITVNTTICAGYCPTMMRVLQAVLP
51 58 L3 87
PLPQVVCTYRDVRFESIRLPGCPRGVDPVVSFPVALSCRCGPCRRSTSDC
101 GGPKDHPLTCDHPQLSGLLFL

FIG. 6

(SEQ ID NO: 5)

Human Follicle Stimulating Hormone (FSH)

1 4 L1 27
NSCELTNITIAIEKEECRFCISINTTWCAGYCYTRDLVYKDPARPKitCT
51 65 L3 81
FKELVYETVRVPGCAHHADSLYTPVATQCHCGKCDSDSTDCTVRGLGPS
101 YCSFGEMKE

FIG. 7

(SEQ ID NO: 6)

Human Platelet-Derived Growth Factor-A (PDGF A-Chain)

1 11 L1 36
SIEEAVPAVCKTRTVIYEIPRSQVDPTSANFLIWPPCVEVKRCTGCCNTS
51 58 L3 88
SVKCQPSRVHHRSVKVAKVEYVRKKPKLKEVQVRLEEHLACATTSLNP
101 DYREEDTGRPRESGKKRKRRLKPT

4/20

FIG. 8

(SEQ ID NO: 7)

Human Platelet-Derived Growth Factor-B (PDGF B-Chain)





FIG. 9

(SEQ ID NO: 8)

Human Vascular Endothelial Growth Factor



5/20

FIG. 10

(SEQ ID NO: 9)

Human Nerve Growth Factor





FIG. 11

(SEQ ID NO: 10)

Human Brain Derived Neurotrophic Factor



7/20

FIG. 15

(SEQ ID NO: 14)

Human Transforming Growth Factor (TGF)- β 2





FIG. 16

(SEQ ID NO: 15)

Human Transforming Growth Factor (TGF)- β 3



8/20

FIG. 17

(SEQ ID NO: 16)

Human Transforming Growth Factor (TGF)- β 4

1 MWPLWLCWAL WVLPLAGPGA ALTEEQLLAS LLRQLQLSEV PVLDRADMEK
51 LVIPAHVRAQ YVLLRRDGD RSRGKRFSQS FREVAGRFLA SEASTHLLVF
101 GMEQRLPPNS ELVQAVLRLF QEPVPQGALH RHGRLSPAAP KARVTVEWLV
151 RDDGSNRTSL IDSRLVSVHE SGWKAFDVTE AVNFWQQLSR PPEPLLQVS
201 VQREHLGPLA SGAHKLVRFA SQGAPAGLGE PQLELHTLDL RDYGAQGDCD
251 PEAPMTEGTR CCRQEMYIDL QGMKWAKNWV LEPPGFLAYE CVGTCQOPPE
301 ALAFNWPFLG PRQCIASETA SLPMIVSIKE GGRTRPOVVS LPNMRVQKCS
351 CASDGALVPR RLQHRPWCIH

FIG. 18

(SEQ ID NO: 17)

Human Neurturin

1 MQRWKAAALA SVLCSSVLSI WMCREGLLLS HRLGPALVPL HRLPRTLDA
51 IARLAQYRAL LQGAPDAMEL RELTPWAGRP PGPRRRAGPR RRRARARLGA
101 RPCGLRELEV RVSELGLGYA SDETVLFRYC AGACEAAARV YDLGLRRLRQ
151 RRRLRRRERV AQPCCRPTAY EDEVSFDAH SRYHTVHEL ARECACV

9/20

FIG. 19

(SEQ ID NO: 18)

Human Inhibin α
(Common to Inhibin A and Inhibin B)

1 MVLHLLLFLL LTPQGGHSCQ GLELARELVL AKVRALFLDA LGPPAVTREG
51 GDPGVRRLPR RHALGGFTHR GSEPEEEEDV SQAILFPATD ASCEDKSAAR
101 GLAQEAEEGL FRYMFRPSQH TRSRQV TSAQ LWFHTGLDRQ GTAASNSSEP
151 LLGLLALSPG GPVAVPMSLG HAPPHWAVLH LATSALSLT HPVLVLLLR
201 PLCTCSARPE ATPFLVAHTR TRPPSGGERA RRSTPLMSWP WSPSALRLQ
251 RPPEEPAAHA NCHRVALNIS FOELGWERWI VYPPSFIFHY CHGGCGLHIP
301 PNLSLPVPGA PPTPAQPYSL LPGAQPCCAA LPGTMRPLHV RTTSDGGYSE
351 KYETVPNLLT QHCACI

FIG. 20

(SEQ ID NO: 19)

Human Inhibin A - β Subunit (α - β A Heterodimer)

1 MPLLWLRGFL LASCWIIIRS SPTPGSEGHS AAPDCPSCAL AALPKDVPNS
51 QPEMVEAVKK HILNMLHLKK RPDVTQPVPK AALLNAIRKL HVGKVGNGY
101 VEIEDDIGRR AEMNELMEQT SEIITFAESG TARKTLHFEI SKEGSDLSVV
151 ERAEVWLFLK VPKANRTRTK VTIRLFQQQK HPQGS�DTGE EAEEVGLKGE
201 RSELLLSEKV VDARKSTWHV FVSSSIQRL LDQGKSSLDV RIACEQCQES
251 GASLVLLGKK KKKEEEGEGK KKGGE GAG ADEEKEQSHR PFLMLQARQS
301 EDHPHRRRRR GLECDGKVNI CCKKQFFVSF KDIGWNDWII APSGYHANYC
351 EGECPSHIAG TSGSSLSFHS TVINHYMRG HSPFANLKSC CVPTKLRPMS
401 MLYYDDGONI IKKDIQNMIV EECGCS

10/20

FIG.21

(SEQ ID NO: 20)

Human Inhibin B - β Subunit (α - β B Heterodimer)

```
1   MDGLPGRALG AACLLLLAAG WLGPEAWGSP TPPPTPAAPP PPPPPGSPGG
51  SQDTCTSCGG FRRPEELGRV DGDFLEAVKR HILSRLQMRG RPNITHAVPK
101 AAMVTALRKL HAGKVREDGR VEIPHLDGHA SPGADGQERV SEIISFAETD
151 GLASSRVRLY FFISNEGNQN LFVVQASLWL YLKLLPYVLE KGSRRKVRVK
201 VYFQEQGHGD RWNMVEKRVD LKRS GWHTFP LTEAIQALFE RGERRNLNDV
251 QCDSCQELAV VPVFVDPGEE SHRPFVVVQA RLGDSRHRIR KRGLECDGRT
301 NLCCRQQFFI DFRLIGWNDW IIAPTGY YGN YCEGSCPAYL AGVPGSASSF
351 HTAVVNQYRM RGLNPGTVNS CCIPTKLSTM SMLYFDDEYN IVKRDVPNMI
401 VEECGCA
```

FIG.22

(SEQ ID NO: 21)

Human Activin A (β A Homodimer)

```
1   MPLLWLRGFL LASCWIIIVRS SPTPGSEGHS AAPDCPSCAL AALPKDVPNS
51  QPEMVEAVKK HILNMLHLKK RPDVTQPVPK AALLNAIRKL HVGKVGENG Y
101 VEIEDDIGRR AEMNELMEQT SEIITFAESG TARKTLHFEI SKEGSDLSVV
151 ERAEVWLFLK VPKANRTRTK VTIRLFQQQK HPQGS LDTGE EAEVGLKGE
201 RSELLLSEKV VDARKSTWHV FPVSSSIQRL LDQGKSSLDV RIACEQCQES
251 GASLVLLGKK KKKEEEGEGK KKG GEGGAG ADEEKEQSHR PFLMLQARQS
301 EDHPHRRRRR GLECDGKVNI CCKKOFFV SF KDIGWNDWII APSGYHANYC
351 EGECPSHIAG TSGSSLSFHS TVINHYRMRG HSPFANLKSC CVPTKLRPMS
401 MLYYDDGONI IKKDIONMIV EECGCS
```

11/20

FIG.23

(SEQ ID NO: 22)

Human Activin B (β B Homodimer)

1 MDGLPGRALG AACLLLLAAG WLGPEAWGSP TPPPTPAAPP PPPPPGSPGG
51 SQDTCTSCGG FRRPEELGRV DGDFLEAVKR HILSRLQMRG RPNITHAVPK
101 AAMVTALRKL HAGKVREDGR VEIPHLDGHA SPGADGQERV SEIISFAETD
151 GLASSRVRLY FFISNEGNQN LFVVQASLWL YLKLLPYVLE KGSRRKVRVK
201 VYFQEQGHGD RWNMVEKRVD LKRSGWHTFP LTEAIQALFE RGERRLNLDV
251 QCDSCQELAV VPVFVDPGEE SHRPFVVVQA RLGDSRHRIR KRGLECDGRT
301 NLCCRQOFFI DFRLIGWNDW IIAPTGYGN YCEGSCPAYL AGVPGSASSF
351 HTAVVNQYRM RGLNPGTVNS CCIPTKLSTM SMLYFDDEYN IVKRDVPNMI
401 VEECGCA

FIG.24

(SEQ ID NO: 23)

Human Müllerian Inhibitory Substance (MIS)

1 MRDLPLTSLA LVLSALGALL GTEALRAEEP AVGTSGLIFR EDLDWPPGIP
51 QEPLCLVALG GDSNGSSSPL RVVGALSAYE QAFLGAVQRA RWGPRDLATF
101 GVCNTGDRQA ALPSLRRLGA WLRDPGGQRL VVLHLEEVTV EPTPSLRFQE
151 PPPGGAGPPE LALLVLYPGP GPEVTVTRAG LPGAQSLCPS RDTRYLVLA
201 DRPAGAWRGS GLALTLQPRG EDSRLSTARL QALLFGDDHR CFTRMTPALL
251 LLPRSEPAPL PAHQQLDTVP FPPPRPSAEL EESPPSADPF LETLTRLVRA
301 LRVPPARASA PRLALDPDAL AGFPQGLVNL SDPAALERLL DGEEPLLLLL
351 RPTAATTGDP APLHDPTSAP WATALARRVA AELQAAAAEL RSLPGLPPAT
401 APLLARLLAL CPGGPGGLGD PLRALLLLKA LQGLRVEWRG RDPRGPGRAQ
451 RSAGATAADG PCALRELSVD LRAERSVLIP ETYQANNCQG VCGWPQSDRN
501 PRYGNHVLL LKMQARGAAL ARPPCCVPTA YAGKLLISLS EERISAHHP
551 NMVATECGCR

12/20

FIG.25

(SEQ ID NO: 24)

Human Bone Morphogenic Protein (BMP)-2

1 MVAGTRCLLA LLLPQVLLGG AAGLVPELGR RKFAAASSGR PSSQPSDEVL
51 SEFELRLLSM FGLKQRPTPS RDAVVPYML DLYRRHSGQP GSPAPDHRLE
101 RAASRANTVR SFHHEESLEE LPETSGKTTR RFFFNLSIP TEEFITSDEL
151 QVFREQMQDA LGNNSSFHHR INIYEIHKPA TANSKFPVTR LLDTRLVNQN
201 ASRWESFDVT PAVMRWTAQG HANHGFFVEV AHLEEKQGVV KRHVRISRSL
251 HQDEHSWSQI RPLLVTFGHD GKGHPLHKRE KRQAKHKQRK RLKSSCKRHP
301 LYVDFSDVGW NDWIVAPPGY HAFYCHGECF FPLADHLNST NHAIVQTLVN
351 SVNSKIPKAC CVPT~~ELSAIS~~ MLYLDENEKV VLKNYQDMVV EGCGR

FIG.26

(SEQ ID NO: 25)

Human Bone Morphogenic Protein (BMP)-3

1 MAGASRLLFL WLGCFCVSLA QGERPKPPFP ELRKAVPGDR TAGGGPDSEL
51 QPQDKVSEHM LRLYDRYSTV QAARTPGSLE GGSQPWRPRL LREGNTRVSF
101 RAAAAETLER KGLYIFNLTS LTKSENILSA TLYFCIGELG NISLSCPVSF
151 GCSHHAQRKH IQIDLSAWTL KFSRNQSLL GHLSVDMAKS HRDIMSWLSK
201 DITQFLRKAK ENEEFLIGFN ITSKGRQLPK RRLPFPEPYI LUYANDAAIS
251 EPESVVSSLQ GHRNFPTGTV PKWDSHIRAA LSIERRKKRS TGVLLPLQNN
301 ELPGAQYQYK KDEVWEERKP YKTLQAQAPF KSKNKKKQRK GPHRKSQTLQ
351 FDEQTLKKAR RKQWIEPRNC ARRYLKVDFA DIGWSEWIIIS PKSFDAYYCS
401 GACQFPMPKS LKPSNHATIQ SIVRAVGVVP GIPEPCCVPE KMSSLSILFF
451 DENKNVVLKV YPNMTVESCA CR

13/20

FIG.27

(SEQ ID NO: 26)

Human Bone Morphogenic Protein (BMP)-3b

1 MAHVPARTSP GPGPQLLLLL LPLFLLLLRD VAGSHRAPAW SALPAAADGL
51 QGDRDLQRHP GDAAATLGPS AQDMVAVHMH RLYEKYSRQG ARPGGGNTVR
101 SFRARLEVVD QKAVYFFNLT SMQDSEMILT ATFHFYSEPP RWPRALEVLC
151 KPRAKNASGR PLPLGPPTRO HLLFRSLSON TATQGLLRGA MALAPPPRGL
201 WQAKDISPIV KAARRDGELL LSAQLDSEER DPGVPRPSY APYILVYAND
251 LAISEPNSVA VTLQRYDFP AGDPEPRAAP NNSADPRVRR AAQATGPLQD
301 NELPGLDERP PRAHAQHFKH HQLWPSPFRA LKPRPGRKDR RKKGQEVFMA
351 ASQVLDFDEK TMQKARRKQW DEPRVCSRRY LKVDFA DIGW NEWIISP KSF
401 DAYYCAGACE FPMPKIVRPS NHATIQSIVR AVGIIPGIPE PCCVPDKMNS
451 LGVLFLDENR NVVLKVYPNM SVDTACR

FIG.28

(SEQ ID NO: 27)

Human Bone Morphogenic Protein (BMP)-4

1 MIPGNRMLMV VLLCQVLLGG ASHASLIPET GKKKVAEIQG HAGGRRSGQS
51 HELLRDFEAT LLQMFGRLRR PQPSKSAVIP DYMRDLRLQ SGEEEEEQIH
101 STGLEYPERP ASRANTVRSF HHEEHLENIP GTSSENSAFRF LFNLSIPEN
151 EAISSAELRL FREQVDQGP WERGFHRINI YEVMKPPAEV VPGHLITRLL
201 DTRLVHHNVT RWETFDVSPA VLRWTREKQP NYGLAIEVTH LHQTRTHQGQ
251 HVRISRSLPQ GSGNWAQLRP LLVTFGHDGR GHALTRRRRA KRSPKHHSQR
301 ARKKKNKNCRR HSLYVDFSDV GWNDWIVAPP GYQAFYCHGD CPFPLADHLN
351 STNHAIVQTL VNSVNSSIPK ACCVPTLSA ISMLYLDEYD KVVLKNYQEM
401 VVEGCGCR

14/20

FIG. 29

(SEQ ID NO: 28)


Human Bone Morphogenetic Protein (BMP)-5 Precursor

1 MHLTVFLLKG IVGFLWSCWV LVGYAKGGLG DNHVHSSFIY RRLRNHERRE
51 IQREILSILG LPHRPRPFSP GKQASSAPLF MLDLYNAMTN EENPEESEYS
101 VRASLAEETR GARKGYASP NGYPRRIQLS RTTPLTTQSP PLASLHDTNF
151 LNDADMVMSF VNLVERDKDF SHQRRHYKEF RFDLTQIPHG EAVTAAEFRI
201 YKDRSNNRFE NETIKISIQ IIKEYTNRDA DLFLDTRKA QALDVGWLVF
251 DITVTSNHVW INPQNNLGLQ LCAETGDGRS INVKSAGLVG RQGPQSKQPF
301 MVAFFKASEV LLRSVRAANK RKNQNRNKSS SHQDSSRMSS VGDYNTSEQK
351 QACKKHELYV SFRDLGWQDW IIAPEGYAAF YCDGECSPPL NAHMNATNHA
401 IVQTLVHLMF PDHVPKPCCA PTKLNAISVL YFDDSSNVIL KKYRNMVVRS
451 CGCH

FIG. 30

(SEQ ID NO: 29)

Human Bone Morphogenetic Protein (BMP)-6/Vgrl

1 SSASDYNSELKTACRKHELYV  40
51 LNAhtNHAIVQTLVHLMNPEYVPKPCCAPTKLNAISVLYFDDNSNVikKY
101 RNMVVRACGCH

15/20

FIG.31

(SEQ ID NO: 30)

Human Bone Morphogenic Protein (BMP)-7/Osteogenic Protein (OP)-1

1 ANVAENSSSDQRQACKKHELYVSFRDLGWQWIIAPEGYAAYYCEGECAFP
51 LNSATNHAIVQTLVHFINPETVPKPCCAPTQLNAISVLYFDDSSNVIKKY
101 RNMVVRACGCH

21 L1 40
81 L3

102

FIG.32

(SEQ ID NO: 31)

Human Bone Morphogenic Protein (BMP)-8/Human Osteogenic Protein (OP)-2

1 MTALPGPLWL LGLALCALGG GPGRLRPPPG CPQRRLGARE RRDVQREILA
51 VLGLPGRPRP RAPPAASRLP ASAPLFMLDL YHAMAGDDDE DGAPAERRLG
101 RADLVMSFVN MVERDRALGH QEPHWKEFRF DLTQIPAGEA VTAAEFRIYK
151 VPSIHLNRT LHVSMFQVVQ EQSNRESDLF FLDLQTLRAG DEGWLVLDDVT
201 AASDCWLLKR HKDLGLRLYV ETEDGHSVDP GLAGLLGQRA PRSQPFVVT
251 FFRASPSPIR TPRAVRPLRR RQPKKSNELP QANRLPGIFD DVHGSHGRQV
301 CRRHELYVSF ODLGWLDWVI APOGYSAYYC EGECSFPLDS CMNATNHAIL
351 QSLVHLMKPN AVPKACCAPT KLSATSVLYY DSSNNVILRK HRNMVVKACG
401 CH

16/20

FIG.33

(SEQ ID NO: 32)

Human Bone Morphogenic Protein (BMP)-10

1 MGSVLVTLCA LFCLAAYLVS GSPIMNLEQS PLEEDMSLFG DVFSEQDGVD
51 FNTLLQSMKD EFLKTLNLSD IPTQDSAKVD PPEYMLELYN KFATDRTSMP
101 SANIIRSFKN EDLFSQPVSF NGLRKYPLLF NVSIPHHEEV IMAELRLYTL
151 VQRDRMIYDG VDRKITIFEV LESKGDNEGE RNMLVLVSGE IYGTNSEWET
201 FDVTDAIRRW QKSGSSTHQL EVHIESKHDE AEDASSGRLE IDTSAQNKHN
251 PLLIVFSDDQ SSDKERKEEL NEMISHEQLP ELDNLGLDSF SSGPGEEALL
301 QMRSNIIYDS TARIRRNAKG NYCKRTPLYI DFKEIGWDSW IIAPPGYEAY
351 ECRGVCNYPL AEHLTPTKHA IIQALVHLKN SQKASKACCV PTKLEPISIL
401 YLDKGVVTYK FKYEGMAVSE CGCR

FIG.34

(SEQ ID NO: 33)

Human Bone Morphogenic Protein (BMP)-11

1 MVLAAPLLLG FLLLALELRP RGEAAEGPAA AAAAAAAAAA AGVGGERSSR
51 PAPSVAPEPD GCPVCVWRQH SRELRLSEIK SQILSKLRLK EAPNISREVV
101 KQLLPKAPPL QQILDLDHDFQ GDALQPEDFL EEDEYHATTE TVISMAQETD
151 PAVQTDGSPL CCHFHFSPKV MFTKVLKAQL WVYLRPVPRP ATVYLQILRL
201 KPLTGEGTAG GGGG~~S~~RRHIR IRSCLKIELHS RSGHWQSIDE KQVLHSWFRQ
251 PQSNWGIEIN AFDPSGTDLA VTSLGPGAEG LHPFMELRVL ENTKRSRRNL
301 GLDCDEHSSE SRCCRYPLTV DFEAFGWDWI IAPKRYKANY CSGQCEYMFM
351 QKYPHTHLVQ QANPRGSAGP CCTPTKMSPI NMLYFNDKQQ IIYGKIPGMV
401 VDRCGCS

17/20

FIG.35

(SEQ ID NO: 34)

I. HUMAN BONE MORPHOGENIC PROTEIN (BMP)-15

1 MVLLSILRIL FLCELVLFME HRAQMAEGGQ SFIALLAEP TLPLIEEMLE
51 ESPGEQPRKP RLLGHSLRYM LELYRRSADS HGHPRENRTI GATMVRLVKP
101 LTSVARPHRG TWHIQILGFP LRPNRGLYQL VRATVVYRHH LQLTRFNLSC
151 HVEPWVQKNP TNHFPSSEGD SSKPSLMSNA WKEMDITQLV QQRFWNNKGH
201 RILRLRFMCQ QQKDSGGLEL WHGTSSLDIA FLLLYFNDTH KSIRKAKFLP
251 RGMEEFMERE SLLRRTRQAD GISA EVTASS SKHSGPENNQ CSLHPFQISF
301 RQLGWDHWII APPFYTPNYC KGTCLRVLRD GLNSPNHAI QNLINQLVDO
351 SVPRPSCVPY KYVPISVLM EANGSILYKE YEGMIAESCT CR

FIG.36

(SEQ ID NO: 35)

Human Norrie Disease Protein (NDP)

[Norrin]

1 MRKHVLAASF SMLSLLVIMG DTDSKTDSSF IMDS DPRRCM RHHYVDSISH
51 PLYKCSSKMV LLARCEGHCS QASRSEPLVS FSTVLKQPFR SSCHCCRPQT
101 SKLKALRLRC SSGMRLTATY RYILSCHCEE CNS

18/20

FIG.37

(SEQ.ID NO: 36)

Human Growth Differentiation Factor (GDF)-1

1 MPPPQQGPCG HLLLLLLALL LPSLPLTRAP VPPGPAAALL QALGLRDEPQ
51 GAPRLRPVPP VMWRLFRRRD PQETRSGSRR TSPGVTLQPC HVEELGVAGN
101 IVRHIPDRGA PTRASEPVSA AGHCPEWTVV FDLSAVEPAE RPSRARLELR
151 FAAAAAAPE GGWELSVQA GQGAGADPGP VLLRQLVPAL GPPVRAELLG
201 AAWARNASWP RSLRLALALR PRAPAACARL AEASLLLVTI DPRLCHPLAR
251 PRRDAEPVLG GPGGACRAR RLYVSFREV GWHRWVIAPRG FLANYCQGQC
301 ALPVALSGSG GPPALNHAUL RALMHAAAPG AADLPCCVPA RLSPISVLFF
351 DNSDNVVLRO YEDMVVDECG CR

FIG.38

(SEQ ID NO: 37)

Human Growth Differentiation Factor (GDF)-5 Precursor

1 MRLPKLLTFL LWYLAULDLE FICTVLGAPD LGQRPQGSRP GLAKAEAKER
51 PPLARNVFRP GGHSYGGGAT NANARAKGGT GQTGGLTQPK KDEPKKLPPR
101 PGGPEPKPGH PPQTRQATAR TVTPKGQLPG GKAPPKAGSV PSSFLLKKAR
151 EPGPPREPKE PFRPPPITPH EYMLSLYRTL SDADRKGNS SVKLEAGLAN
201 TITSFIDKGQ DDRGPVVRKQ RYVFDISALE KDGLLGAELE ILRKKPSDTA
251 KPAVPRSRRA AQLKLSSCPS GRQPAALLDV RSVPGLDGSG WEVFDIWKLF
301 RNFKNQAQLC LELEAWERGR TVDLRGLGFD RAARQVHEKA LFLVFGRTKK
351 RDLFFNEIKA RSGQDDKTVY EYLFSQRRKR RAPSATRQK RPSKNLKARC
401 SRKALHVNEK DMGWDDWIIA PLEYEAFHCE GLCEFFPLRSH LEPTNHAVIQ
451 TLMNSMDPES TPPTCCVPT LSPISILFID SANNVYKQY EDMVVESCGC
501 R

19/20

FIG.39

(SEQ ID NO: 38)

Human Growth Differentiation Factor (GDF)-8 [Myostatin]

1 MQKLQLCVYI YLFMLIVAGP VDLNENSEQK ENVEKEGLCN ACTWRQNTKS
51 SRIEAIKIQI LSKLRLETAP NISKDVIRQL LPKAPPLREL IDQYDVQRDD
101 SSDGSLEDDD YHATTETIIT MPTESDFLMQ VDGKPKCCFF KFSSKIQYNK
151 VVKAQLWIYL RPVETPTTVF VQILRLIKPM KDGTRYTGIR SLKLDMPNGT
201 GIWQSIDVKT VLQNLWKQPE SNLGIEIKAL DENGHD LAVT FPGPGEDGLN
251 PFLEVKVTD T PKRSRRDFGL DCDEHSTESR CCRYPLTVDF EAFGWDWIIA
301 PKRYKANYCS GECEFVFLQK YPHTHLVHQA NPRGSAGPCC TPTKMSPINM
351 LYFNGKEQII YGKIPAMVVD RCGCS

FIG.40

(SEQ ID NO: 39)

Human Growth Differentiation Factor (GDF)-9

1 MARPNKFLW FCCFAWLCPF ISLGSQASGG EAQIAASAEL ESGAMPWSLL
51 QHIDERDRAG LLPALFKVLS VGRGGSPRLQ PDSRALHYMK KLYKTYATKE
101 GIPKSNRSHL YNTVRLFTPC TRHKQAPGDQ VTGILPSVEL LFNLDRIITV
151 EHLLKSVLLY NINNSVSFSS AVKVCVNLMI KEPKSSRTL GRAPYSFTFN
201 SQFEFGKKHK WIQIDVTSLL QPLVASNKRS IHMSINF TCM KDQLEHPSAQ
251 NGLFNMTLVS PSLILYLNDT SAQAYHSWYS LHYKRRPSQG PDQERSLSAY
301 PVGEEAAEDG RSSHHRHRRG QETVSSELKK PLGPASFNLS EYFRQFLLPQ
351 NECELHDFRL SFSOLKWDNW IVAPHRYNPR YCKGDCPRAV GHRYGSPVHT
401 MVQNIIEYKL DSSVPRPSCV PAKYSPLSVL TIEPDGSIAY KEYEDMIATK
451 CTCR

20/20

FIG.41

(SEQ ID NO: 40)

Human Artemin (GDNF)

1 MPGLISARGQ PLLEVLPPQA HLGALFLPEA PLGLSAQPAL WPTLAALALL
51 SSVAEASLGS APRSPAPREG PPFVLASPAG HLPGGRTARW CSGRRARRPPP
101 QPSRPAPPPP APPSALPRGG RAARAGGPGS RARAAGARGC RLRSOLVPVR
151 ALGLGHRSDE LVRFRFCSGS CRRARSPHDL SLASLLGAGA LRPPPGSRPV
201 SQPCCRPTRY EAVSFMDVNS TWRTVDRLSA TACGCLG

FIG.42

(SEQ ID NO: 41)

Human Glial Cell Derived Factor (GDNF)

[Persephin]

1 MAVGKFLLS LLLSLQLGQ GWGPDARGVP VADGEFSSEQ VAKAGGTWLG
51 THRPLARLRR ALSGPCQLWS LTLSVAELGL GYASEEKVIF RYCAGSCPRG
101 ARTQHGLALA RLQGQGRAHG GPCCRPTRYT DVAFLDDRHR WORLPQLSAA
151 ACGCGG